Assembly Biosciences Q2 net loss narrows as revenue rises
ASMB•Result drivers
- Gilead collaboration revenue - Higher Q2 revenue reflected timing and progress of activities under the Gilead collaboration, including a $5.1 million cumulative catch-up adjustment.
- R&D expenses - Lower R&D expenses were driven by completion of clinical trials, partially offset by increased research and higher employee-related costs.
- Financing - $115 million gross financing was completed to support advancement of pipeline programs.
Q2 revenue rises, net loss narrows
- US biotech firm's Q2 revenue from Gilead collaboration rose year over year, and net loss narrowed.
- Lower net loss was driven by higher revenue, reduced R&D expenses and increased interest income.
- The company completed $115 million in financing, with cash runway projected into 2029.
Pipeline outlook and upcoming trials
- The company expects to initiate a Phase 2 trial for GS-1179 in genital herpes by year-end 2026.
- Assembly Bio plans to start a Phase 2 study of ABI-6250 in chronic HDV by year-end 2026.
- The company anticipates a Phase 2 study of ABI-6250 in cholestatic liver diseases in Q1 2027.
Key financial details and analyst coverage
Related News
Afya releases investor presentation on Brazil medical education, physician practice solutions ecosystem
AFYA•
Trailblazer Acquisition FY26 Q2 net income rises to $2.37 million; FY26 H1 net income climbs to $4.64 million
BLZR•
